The Cancer Genome Atlas (TCGA) pilot project generates comprehensive genomic and epigenomic data to provide new insights into the biology of cancer include the identification of novel mutations and pathways. Large-scale genomics projects significantly increase our basic understanding of cancer by: 1) providing comprehensive, complex data sets for analysis, 2) ensuring that the data have minimal variation due to samples, biomolecules and laboratory methods and 3) enabling clinically relevant analytic approaches that are not possible with smaller, less complete data sets. This session aims to provide an update on TCGA and how the data are being using by the members of TCGA research network as well as the cancer research community for discoveries of novel clinical correlations that can enable the discovery of new diagnostic markers and therapeutic targets.
NCI/NIH-Sponsored Sessions: Translating Knowledge from the Cancer Genome Atlas (TCGA) to Understand and Control Cancer

Daniela Gerhard. National Cancer Institute, Bethesda, MD

Peter J. Park. Children's Hospital, Harvard Medical School, Boston, MA

Ingo Mellinghof. Mem. Sloan-Kettering Cancer Ctr., New York, NY

Paul T. Spellman. Lawrence Berkeley National Laboratory, Berkeley, CA

Douglas A. Levine. Mem. Sloan-Kettering Cancer Ctr., New York, NY

David B. Agus. Cedars-Sinai Medical Ctr., Los Angeles, CA

Anna D. Barker. National Cancer Inst., Bethesda, MD,